What is the hybrid diagnostic assay that combines multiplex ligation‑dependent probe amplification (MLPA) with next‑generation sequencing (NGS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

MLPA-NGS Hybrid Diagnostic Assay

The hybrid diagnostic assay combining multiplex ligation-dependent probe amplification (MLPA) with next-generation sequencing (NGS) is called digitalMLPA (also referred to as MLPA-based NGS or digital MLPA).

What is digitalMLPA?

DigitalMLPA is a novel molecular diagnostic technique that integrates the standard MLPA procedure with NGS technology to enable high-throughput screening of large numbers of genomic fragments and samples simultaneously 1, 2, 3. This hybrid approach overcomes the traditional limitation of conventional MLPA, which can only accommodate a maximum of 60 probes per test 1.

Technical Characteristics

The assay works by:

  • Following the standard MLPA workflow (denaturation, hybridization of probes, ligation, and PCR amplification) 4
  • Incorporating additional indices for detection that allow multiplexing 1
  • Using NGS platforms (particularly Illumina) for readout instead of capillary electrophoresis 1, 2
  • Enabling analysis of up to 1000 target sequences simultaneously 3, compared to the 50 probes maximum in conventional MLPA 4

Clinical Applications

DigitalMLPA has demonstrated robust performance in detecting:

  • Copy number alterations (CNAs) including deletions, duplications, and amplifications 2, 3
  • Large-scale chromosomal abnormalities such as whole chromosome gains/losses and hyperdiploidy 2, 3
  • Intragenic deletions and fusion genes 3
  • Point mutations (proof of principle shown with BRAF V600E detection) 2
  • Subclonal alterations present in as little as 20-30% of neoplastic cells 3

Validated Disease Applications

The technique has been successfully validated in:

  • Hematologic malignancies: Multiple myeloma 2, T- and B-cell acute lymphoblastic leukemia 3, and lymphomas 5
  • Muscular dystrophies: Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA) 1, 6
  • Myelodysplastic syndromes 7

Performance Metrics

In lymphoblastic leukemia, digitalMLPA demonstrated:

  • Diagnostic sensitivity: 98.9%
  • Specificity: 97.8%
  • Congruency with conventional methods (iFISH, MLPA): 95% 2, 3

Advantages Over Conventional MLPA

  • Dramatically increased probe capacity (up to 1000 vs. 60 targets) 1, 3
  • Detailed mapping of complex CNAs, particularly useful for chromosome 1 abnormalities where 24 different patterns were identified in a single study 2
  • Detection of aberrations missed by conventional methods - in multiple myeloma, digitalMLPA revealed 156 CNAs not detected by iFISH or conventional MLPA in 80% of patients 2
  • Precise characterization of hyperdiploid karyotypes not efficiently achievable by other methods 2
  • Cost-effectiveness compared to comprehensive NGS panels while maintaining high throughput 4, 1

Important Caveats

The sensitivity for detecting heterozygous deletions requires ≥20% tumor cell content, and ≥40% for duplication detection 4. This is a critical limitation when analyzing samples with low tumor burden or high normal cell contamination.

References

Guideline

acute myelogenous leukemia - current recommendations and approaches in molecular-genetic assessment.

Romanian journal of internal medicine = Revue roumaine de medecine interne, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.